CSPC present the results of two latest clinical trials of two investigational products in this ESMO Congress

The annual European Society for Medical Oncology (ESMO) Congress will take place from October 20 to 24, 2023, in Madrid, Spain. As one of the most prestigious and influential international conferences, the ESMO Congress attracts a large number of experts and scholars in relevant fields every year. CSPC will present the results of two latest clinical trials of two investigational products in this ESMO Congress.

1.

Study title: A Phase I Dose-Expansion Study of SYHA1813, A Small-Molecule Inhibitor Targeting VEGFR/CSF1R in Patients with Recurrent Meningeal Carcinomatosis

Enrollment type: Mini Oral report

Enrollment ID: 506MO

Study introduction: This is an open-label, multi-center phase I clinical trial led by Professor Li Wenbin from Beijing Tiantan Hospital CMU and designed to evaluate the safety, tolerance, pharmacokinetics, and preliminary efficacy of SYHA1813 in patients with recurrent or advanced solid tumor.

2.

Study title: A Phase I Clinical Trial of Anti-HER2 ADC DP303c in Patients with Advanced HER2-Expressing Solid Tumor

Enrollment type: Mini Oral report

Enrollment ID: 385MO

Study introduction: This is a multi-center, single-arm phase I clinical trial led by Professor Hu Xichun from Fudan University Shanghai Cancer Center and designed to evaluate the safety, tolerance, preliminary efficacy, pharmacokinetics, and immunogenicity of DP303c in patients with advanced HER2-expressing solid tumor.